Galapagos receives transparency notification from Johnson & Johnson
March 01 2016 - 4:09PM
Galapagos NV (Euronext & NASDAQ: GLPG) received a
transparency notification from Johnson & Johnson.
Pursuant to Belgian transparency legislation[1],
Galapagos received a transparency notification on 1 March 2016 from
Johnson & Johnson who notified that the 1,113,964 shares held
by Johnson & Johnson Group Holdings GmbH (as legal successor to
Tibotec-Virco Comm. VA) and the 1,236,097 shares held by Crucell
Holland B.V., both subsidiaries of Johnson & Johnson, were sold
on 25 February 2016. Johnson & Johnson's shareholding thus
decreased below the 5% notification threshold. Johnson &
Johnson continues to be a shareholder in Galapagos. The full
transparency notice is available on the Galapagos website.
About Galapagos Galapagos (Euronext &
NASDAQ: GLPG) is a clinical-stage biotechnology company specialized
in the discovery and development of small molecule medicines with
novel modes of action. Our pipeline comprises three Phase 2,
three Phase 1, five pre-clinical, and 20 discovery studies in
cystic fibrosis, inflammation, fibrosis, osteoarthritis and other
indications. We have discovered and developed filgotinib: in
collaboration with Gilead we aim to bring this JAK1-selective
inhibitor for inflammatory indications to patients all over the
world. Galapagos is focused on the development and
commercialization of novel medicines that will improve people's
lives. The Galapagos group, including fee-for-service
subsidiary Fidelta, has approximately 400 employees, operating from
its Mechelen, Belgium headquarters and facilities in The
Netherlands, France, and Croatia. More information at
www.glpg.com.
CONTACT |
|
|
|
|
|
Investors: |
Media: |
Elizabeth Goodwin |
Evelyn Fox |
VP IR & Corporate
Communications |
Director Communications |
+1 781 460 1784 |
+31 6 53 591 999 |
ir@glpg.com |
communications@glpg.com |
Galapagos Forward-Looking Statements
This release may contain forward-looking statements.
Galapagos cautions the reader that forward-looking statements are
not guarantees of future performance. Forward-looking
statements involve known and unknown risks, uncertainties and other
factors which might cause the actual results, financial condition
and liquidity, performance or achievements of Galapagos, or
industry results, to be materially different from any historic or
future results, financial conditions and liquidity, performance or
achievements expressed or implied by such forward-looking
statements. In addition, even if Galapagos' results,
performance, financial condition and liquidity, and the development
of the industry in which it operates are consistent with such
forward-looking statements, they may not be predictive of results
or developments in future periods. Among the factors that may
result in differences are the inherent uncertainties associated
with competitive developments, clinical trial and product
development activities and regulatory approval requirements,
Galapagos' reliance on collaborations with third parties, and
estimating the commercial potential of our product
candidates. A further list and description of these risks,
uncertainties and other risks can be found in the company's
Securities and Exchange Commission filing and reports, including in
the company's prospectus filed with the Securities and Exchange
Commission on May 14, 2015 and subsequent filings and reports filed
by the company with the Securities and Exchange Commission.
Given these uncertainties, the reader is advised not to place any
undue reliance on such forward-looking statements. These
forward-looking statements speak only as of the date of publication
of this document. Galapagos expressly disclaims any
obligation to update any such forward-looking statements in this
document to reflect any change in its expectations with regard
thereto or any change in events, conditions or circumstances on
which any such statement is based or that may affect the likelihood
that actual results will differ from those set forth in the
forward-looking statements, unless specifically required by law or
regulation.
[1] Belgian Act of 2 May 2007 on the disclosure of
major shareholdings in issuers whose shares are admitted to trading
on a regulated market
GLPG receives transparency notification from J&J
http://hugin.info/133350/R/1990623/731403.pdf
HUG#1990623
Galapagos (EU:GLPG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Galapagos (EU:GLPG)
Historical Stock Chart
From Jul 2023 to Jul 2024